- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source: The post is based on the article “Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval” published in PIB on 7th September 2022
What is the News?
Bharat Biotech International Limited (BBIL) gas announced that iNCOVACC (BBV154) vaccine has received approval under Restricted Use in Emergency Situation for ages 18 and above.
What is iNCOVACC?
It is an intra-nasal Covid-19 vaccine.
Developed by: Bharat Biotech International Limited (BBIL)
Working: It is a recombinant replication-deficient adenovirus vectored vaccine with a prefusion stabilized spike protein. It uses a modified chimpanzee adenovirus which cannot replicate in the body to carry Covid spike protein to induce immunity.
Usage: This vaccine will be used for primary immunization against COVID-19 in the 18+ age group for restricted use in emergency situations.
Storage: The vaccine is stable between two and eight degrees Celsius for easy storage and distribution.
What are the benefits of iNCOVACC?
1) Likely to block both infection and transmission of COVID-19, 2) Non-invasive and needle-free, 3) Easy to administer as it does not require trained healthcare workers, 4) Eliminates needle-associated risks (injuries and infections), 5) High compliance — ideally suits children and adults and 6) Scalable manufacturing — able to meet global demand.
